(+)-JQ1

Catalog No.S7110

(+)-JQ1 Chemical Structure

Molecular Weight(MW): 456.99

(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.

Size Price Stock Quantity  
USD 270 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

8 Customer Reviews

  • The BET protein inhibitor JQ1 reduces c-Myc expression and attenuates primary MCC cell proliferation. A, decreased c-Myc expression in MCC-3 and MCC-5 treated with JQ1 (800 nmol/L) for 72 hours by qRT-PCR and immunoblotting. The mRNA expression of target genes was normalized to that of MRPS2 and a value of 1.0 was assigned to the mRNA expression of target genes in the control group (means+SEM; **, P < 0.01 vs. control); b-actin was used as a loading control for immunoblotting.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

    Immunohistochemical staining of xenograft tumor tissues. Immunohistochemical staining of xenograft tumor tissues with the indicated antibodies. p21-, p27-, p57-, and Ki67 positive cells (brown staining) were quantified at x400 magnification (meansSEM;**, P < 0.01;***, P < 0.001 vs. control); scale bars, 10 um.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

  • (D) Effect of JQ1 on alterations of actin cytoskeleton in VEGF-induced HUVECs. The cells were pretreated with DMSO or JQ1 (100 nM) for 6 h, and stimulated with VEGF (10 ng/mL) for 12 h. F-actin (red) and nuclei (blue) were stained with phalloidin and DAPI, respectively. Representative images from 3 independent experiments.

    Sci Rep, 2016, 6:23770.. (+)-JQ1 purchased from Selleck.

    Sensitivity of BEZ235-resistant cells to JQ-1 using the MTT assay.

    Oncotarget, 2016, 6(7):5134-46.. (+)-JQ1 purchased from Selleck.

  • B. Repressed MCC-3 xenograft tumor growth upon combined treatment with MLN0128 and JQ1. Tumor bearing mice were treated with MLN0128 or vehicle at 1 mg/kg/day by oral gavage and JQ1 or vehicle at 50 mg/kg/day by i.p. injection for a period of 30 days. C. A more effective reduction of MCC-3 xenograft tumor growth in the group treated with combined therapy. Fold-reduction of tumor growth was calculated as average tumor growth of control group divided by average tumor growth of treatment group. Tumor growth was calculated as final average tumor volume minus initial average tumor volume in each group.

    Oncotarget, 2016, 7(6):6576-92.. (+)-JQ1 purchased from Selleck.

    JQ1 induces cell cycle arrest and apoptosis in Cal27 cells. (C) Cal27 cells were treated with JQ1 for 24 h and whole cell lysates were tested by western blot assays for the expression of cleaved-caspase-3. GAPDH was used as a loading control. (D) Apoptosis of Cal27 cells treated with JQ1 at 0 and 0.5 µM JQ1; *P<0.05 vs. control (the DMSO group)

    Oncol Rep, 2016, 36(4):1989-96.. (+)-JQ1 purchased from Selleck.

  • immunofluorescence staining of BRD4 in ACC-LM and ACC-83 cells treated with JQ1 at the concentration of 1 µM for 24 h (×200).

    Biol Res, 2017, 50(1):19. (+)-JQ1 purchased from Selleck.

    Effect of BET domain family inhibition on AMI damage in cardiomyocytes. (A) LDH and (B) CK-MB activity in the serum. #P<0.01 vs. sham group; @P<0.05 and &P<0.01 vs. AMI group. BET, bromodomain and extra-terminal; AMI, acute myocardial infarction; LDH, lactate dehydrogenase; CK-MB, creatine kinase MB isoenzyme.

    Exp Ther Med, 2015, 10(6):2319-2324.. (+)-JQ1 purchased from Selleck.

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description (+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.
Features (+)-JQ1 is more effective than (-)-JQ1.
Targets
BRD4 (2) [1]
(Cell-free assay)
BRD4 (1) [1]
(Cell-free assay)
33 nM 77 nM
In vitro

(+)-JQ1 enantiomer binds directly into the Kac binding site of BET bromodomains. (+)-JQ1 (500 nM) binds BRD4 competitively with chromatin resulting in differentiation and growth arrest of NMC cells. (+)-JQ1 (500 nM) attenuates rapid proliferation of NMC 797 and Per403 cell lines as demonstrated by reduced Ki67 staining. (+)-JQ1 (500 nM) potently decreases expression of both BRD4 target genes in NMC 797 cells. (+)-JQ1 inhibits cellular viability with IC50 of 4 nM in NMC 11060 cells. [1] (+)-JQ1 results in robust inhibition of MYC expression in MM cell lines. (+)-JQ1 inhibits proliferating of KMS-34 and LR5 with IC50 of 68 nM and 98 nM, respectively. (+)-JQ1 (500 nM)-treated MM.1S cells results in a pronounced decrease in the proportion of cells in S-phase, with a concomitant increase in cells arrested in G0/G1. (+)-JQ1 (500 nM) results in pronounced cellular senescence by beta-galactosidase staining. (+)-JQ1 (800 nM) exposure leads to a significant reduction in cell viability among the majority of CD138+ patient-derived MM samples tested. [2] (+)-JQ1 inhibits growth of LP-1 cells with GI50 of 98 nM. (+)-JQ1 (625 nM) results in an increase in the percentage of LP-1 cells in G0/G1. (+)-JQ1 (500 nM) suppresses the expression of MYC, BRD4 and CDK9 in LP-1 cells. [3] (+)-JQ1 (1 μM) activates HIV transcription in latently infected Jurkat T cells. (+)-JQ1 (50 μM) stimulates predominantly Tat-dependent HIV transcription in both Jurkat and HeLa cells. (+)-JQ1 (5 μM) induces Brd4 dissociation enables Tat to recruit SEC to HIV promoter and induce Pol II CTD phosphorylation and viral transcription in J-Lat A2 cells. JQ1 enables Tat to increase CDK9 T-loop phosphorylation and partially dissociates P-TEFb from 7SK snRNP in Jurkat T cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K1  NUDsZ5ZmS2WubDDWbYFjcWyrdImgRZN{[Xl? M3;0XVI2OC93MECvNVAxOCCwTR?= MXeyOE81QC95MjDo M1LKeWROW09? NEHoRZRqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz NHL1e4gzPjdyN{i4NS=>
BCPAP NITGZlFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NI\sR3QzPTBxNUCwM|ExODBibl2= MYqyOE81QC95MjDo M1XVfGROW09? NYTZUVlUcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmNSCjbnSgeIlu\S1iZHXw[Y5l\W62IH3hco5meg>? M3XkO|I3PzB5OEix
K1  MVXD[YxtKEO7Y3zlJGF{e2G7 NHS3[2IzPTBxNUCwM|ExODBibl2= NF7vVJI4OiCq M1myb2ROW09? NWL2[3VQ[XK{ZYP0d{Bk\WyuIHP5Z4xmKGG2IFewM2cyKHCqYYPl NIf6XZgzPjdyN{i4NS=>
BCPAP NGX3fVhE\WyuIFP5Z4xmKEG|c3H5 NGXPRWIzPTBxNUCwM|ExODBibl2= NGrvT3Q4OiCq NV7BXFhLTE2VTx?= MnrYZZJz\XO2czDj[YxtKGO7Y3zlJIF1KEdyL1exJJBp[XOn NXzrZnN4OjZ5MEe4PFE>
Hep3B NYLicGZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7JUXExNTFyIN88US=> NFXub5Q2KGR? MV;EUXNQ MkfyTWM2OD1yLkC4JO69VQ>? MX:yOlU4PTF4Nx?=
HCCLM3 M3mwe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVKwMVExKM7:TR?= MoPyOUBl NXT0UFNQTE2VTx?= MW\JR|UxRTBwMUSg{txO MX2yOlU4PTF4Nx?=
HuH7 NGfMOWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYCwMVExKM7:TR?= Ml[4OUBl Mm[wSG1UVw>? NUXiTmdrUUN3ME2wMlIyKM7:TR?= MXKyOlU4PTF4Nx?=
HepG2 MlXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlz3NE0yOCEQvF2= NUL5ZWVTPSCm MXPEUXNQ M2\nRWlEPTB;MD6zOEDPxE1? NWTCSJpxOjZ3N{WxOlc>
SMMC7721 MmezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWK0Z5hrOC1zMDFOwG0> NGLO[WE2KGR? MYXEUXNQ M2rBU2lEPTB;MD60NUDPxE1? MkTONlY2PzVzNke=
BEL7402 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fJeVAuOTBizszN Mmr1OUBl NI\VdHVFVVOR M133cmlEPTB;MD60O{DPxE1? NVvV[VcyOjZ3N{WxOlc>
MHCC97H NW[4VodYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXXc|AxNTFyIN88US=> NG\p[WE2KGR? MVnEUXNQ MXjJR|UxRTBwNEGg{txO MnnRNlY2PzVzNke=
Hep3B MWHD[YxtKEO7Y3zlJGF{e2G7 Ml7DNE4yNzBwNT:yMlUh|ryP MYe0PEBp NIjtRoFFVVOR MofCcIVi\HNidH:gZUB{fWK|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhUEOFIHPlcIx{KGmwIIP1Zk1IOSCyaHHz[eKh MlTONlY2PzVzNke=
HCCLM3 MniyR4VtdCCFeXPs[UBCe3OjeR?= NUXqSWVyOC5zL{CuOU8zNjVizszN MnfPOFghcA>? M3zqXWROW09? M2K4Xoxm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKEiFQzDj[YxteyCrbjDzeYIuTzFicHjhd4XDqA>? NYLUbFBlOjZ3N{WxOlc>
Hep3B M17NOmFxd3C2b4Ppd{BCe3OjeR?= M2LzSVAvOS9yLkWvNk42KM7:TR?= NUXkZotQPDhiaB?= MUDEUXNQ M3rFT4FkfGm4YYTld{Bk[XOyYYPlMVMh[W6mIHPhd5Bie2VvOTDlfJBz\XO|aX;uJIFv\CCrbnT1Z4VlKFCDUmCgZ4xm[X[jZ3WgZZMhf2WubDDhd{BkgXSxY3jyc41mKGNicnXs[YF{\SCrboTvJJRp\SCleYTvdIxie21iZoLvcUBucXSxY3jvcoRzcWF? NHnBb2MzPjV5NUG2Oy=>
HCCLM3 NX\QVFk2SXCxcITvd4l{KEG|c3H5 MXGwMlEwOC53L{KuOUDPxE1? NG\WV2M1QCCq NGfBNZRFVVOR NXLzRmR1[WO2aY\heIV{KGOjc4Dhd4UuOyCjbnSgZ4F{eGG|ZT25JIV5eHKnc4Ppc44h[W6mIHnu[JVk\WRiUFHSVEBkdGWjdnHn[UBieyC5ZXzsJIF{KGO7dH;jbJJwdWViYzDy[Yxm[XOnIHnueI8hfGinIHP5eI9xdGG|bTDmdo9uKG2rdH;jbI9v\HKrYR?= M3X6XVI3PTd3MU[3
A549 M3flRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFywc2sxNjFvMUCg{txO NGHZenY4OiCq NYHabG1ncW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M3nDe|I3PDF3MkK1
H157 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\MXYI3OC5zLUGwJO69VQ>? MXG3NkBp Mm\kbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MWWyOlQyPTJ{NR?=
H1299 NWq4dIRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVSwMlEuOTBizszN MXe3NkBp MVHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NUnsXolbOjZ2MUWyNlU>
A549 MWXGeY5kfGmxbjDBd5NigQ>? M2\EeVEwOi53L{Wg{txO NHnHdY4yOiCq NIjFWIPDqHenYXvsfUBl\WO{ZXHz[YQhSmOuLUKgcIV3\Wy| M2LXblI3PDF3MkK1
H1299 MlizSpVv[3Srb36gRZN{[Xl? NYi0b3NCOS9{LkWvOUDPxE1? MYmxNkBp MYhCpJdm[WuueTDk[YNz\WG|ZXSgRoNtNTJibHX2[Yx{ NHnxV5AzPjRzNUKyOS=>
H157 M3jhOmZ2dmO2aX;uJGF{e2G7 MVqxM|IvPS93IN88US=> NITrTIUyOiCq MnzS[IVkemWjc3XkJGRTPCCneIDy[ZN{cW:w MXmyOlQyPTJ{NR?=
H1299 M{e1e2Z2dmO2aX;uJGF{e2G7 NH7mN3MyNzJwNT:1JO69VQ>? NVrpWZp3OTJiaB?= NGDpPJBl\WO{ZXHz[YQhTFJ2IHX4dJJme3Orb36= NF;WdnczPjRzNUKyOS=>
C8161 Mn3uR4VtdCCYaXHibYxqfHliQYPzZZk> M4rVclAuOiEQvF2= MlX6OEBl NGnUTY5FVVOR NGS0VZFl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MlXQNlY{QTd{MkO=
Mel285 M4XSOGNmdGxiVnnhZoltcXS7IFHzd4F6 NYTte4V3OC1{IN88US=> MXG0JIQ> MYHEUXNQ NXPMVnBL\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MXmyOlM6PzJ{Mx?=
Mel290 NWTLTXZ2S2WubDDWbYFjcWyrdImgRZN{[Xl? NVrNZpg3OC1{IN88US=> MnPrOEBl M{nPUmROW09? MV7k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NFPjW4wzPjN7N{KyNy=>
92.1 MV3D[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mn;1NE0zKM7:TR?= M4qyelQh\A>? M3\mbmROW09? NGPoR5Nl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MnHLNlY{QTd{MkO=
Omm1.3 MXzD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NX\Q[3k{OC1{IN88US=> M4njb|Qh\A>? MmLRSG1UVw>? M4[1[oRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M1LTflI3Ozl5MkKz
Mel202 NHnnV45E\WyuIG\pZYJqdGm2eTDBd5NigQ>? NUL0cld6OC1{IN88US=> M3LvdlQh\A>? M2T1cmROW09? M3u0coRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NIXCXHUzPjN7N{KyNy=>
Mel270 NIDTOplE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NF:wWlYxNTJizszN NHv5[W41KGR? MX3EUXNQ Mn3p[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M2XsS|I3Ozl5MkKz
Omm1 M1fldWNmdGxiVnnhZoltcXS7IFHzd4F6 MVSwMVIh|ryP M4nESlQh\A>? NV3Y[|ZoTE2VTx?= Ml;u[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M2jhdFI3Ozl5MkKz
92.1 MWTBdI9xfG:|aYOgRZN{[Xl? M1;ye|UxOCCwTR?= M{j0fFQ5KGh? MX;EUXNQ NX7vXo1WcW6mdXPld{BieG:ydH;zbZM> NFnFd5MzPjN7N{KyNy=>
Omm1.3 MYXBdI9xfG:|aYOgRZN{[Xl? MXm1NFAhdk1? M2\BSFQ5KGh? NH[xU5ZFVVOR NXPTVXQ{cW6mdXPld{BieG:ydH;zbZM> M4HmSlI3Ozl5MkKz
92.1 MoXWR4VtdCCFeXPs[UBCe3OjeR?= NUGwc5NFPTByIH7N MViyOE81QC95MjDo NWL5XI9yTE2VTx?= NVHwS|ZVcW6mdXPld{B1cGViY3XscEBi[2O3bYXsZZRqd25iYYSgd5VjNUdzwrC= MUOyOlM6PzJ{Mx?=
Omm1.3 M{L4SGNmdGxiQ4njcIUhSXO|YYm= MUe1NFAhdk1? MlrNNlQwPDhxN{KgbC=> M4XQdGROW09? M3\vfIlv\HWlZYOgeIhmKGOnbHygZYNkfW23bHH0bY9vKGG2IIP1Zk1IOcLi NVvGUXI5OjZ|OUeyNlM>
A549 M{HOOWZ2dmO2aX;uJGF{e2G7 MlniNVAxNzRyMD:xNFAxKG6P NXfz[JRVOjRiaB?= MkXVeZBz\We3bHH0[ZMh[W6mIHHjeIl3[XSnczDTTXJVOQ>? MWqyOlIyOjF7OR?=
MCF-7 MoP5SpVv[3Srb36gRZN{[Xl? MXOxNFAwPDByL{GwNFAhdk1? MnmwNlQhcA>? NIjoc4R2eHKnZ4XsZZRmeyCjbnSgZYN1cX[jdHXzJHNKWlRz MYKyOlIyOjF7OR?=
HEK293 NUPuS2pHTnWwY4Tpc44hSXO|YYm= M2HLUVExOC92MECvNVAxOCCwTR?= NXy2V2lLOjRiaB?= NH;oTHR2eHKnZ4XsZZRmeyCjbnSgZYN1cX[jdHXzJHNKWlRz NVjnTpJoOjZ{MUKxPVk>
858 MUnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M4LB[|AuOSEQvF2= M4\YWVUh\A>? MUnEUXNQ M17tR4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M4\YXVI3OjB4M{Oz
DDR2L63V NITrfJBE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M4DYSFAuOSEQvF2= NIfOSpA2KGR? MkHlSG1UVw>? MmXi[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M{HofFI3OjB4M{Oz
BE(2)-C M4rnbGNmdGxiVnnhZoltcXS7IFHzd4F6 MkT4NUDPxE1? NELuZXYyNTRiZB?= NELlNopl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? M{jnOlI3ODZ5NE[0
IMR-32 M1rsZmNmdGxiVnnhZoltcXS7IFHzd4F6 NXXaZlhGOSEQvF2= MmrpNU01KGR? M{\aXoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 MnPjNlYxPjd2NkS=
JF M{LRdWNmdGxiVnnhZoltcXS7IFHzd4F6 M4XNZlEh|ryP M2XNWFEuPCCm MXvk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=> M13kWFI3ODZ5NE[0
BE(2)-M17 MYfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MYmxJO69VQ>? MofGNU01KGR? M3\uXoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 NVvQdYZ6OjZyNke0OlQ>
SK-N-SH NEC1[2VE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NWDyZolSOSEQvF2= NIToTGUyNTRiZB?= NFKwelJl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? MnjsNlYxPjd2NkS=
SK-N-DZ  NYfXdFJWS2WubDDWbYFjcWyrdImgRZN{[Xl? MX:xJO69VQ>? M2D2PFEuPCCm Moe3[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> NVXoT5BKOjZyNke0OlQ>
HMC-1.1  NHz0VWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnSzOU02ODByIH7N Mo\XOFghcA>? NX\t[pNTTE2VTx?= Mn24bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NEL6eWIzPjB3NUOwNy=>
HMC-1.2 M1rYN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIWyZpc2NTVyMECgcm0> M2flV|Q5KGh? NUTycIFOTE2VTx?= NFTySYlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MmnuNlYxPTV|MEO=
ROSA KIT WT  NILGRlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPGNYc2NTVyMECgcm0> MXu0PEBp M4PsT2ROW09? M13lSYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MlfvNlYxPTV|MEO=
ROSA KIT D816V NGLYRYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjTc|dFPS13MECwJI5O Mn7COFghcA>? MoPDSG1UVw>? NV:zV5pbcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MkjaNlYxPTV|MEO=
HMC-1.1  Mk\SRZBweHSxc3nzJGF{e2G7 M2\5[VIxOC13MECwJI5O MYW0PEBp NXHGfmdyTE2VTx?= MWTpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MXiyOlA2PTNyMx?=
HMC-1.2 NEjlZmdCeG:ydH;zbZMhSXO|YYm= NWfrZ21vOjByLUWwNFAhdk1? NVXuT2k2PDhiaB?= NWDUfIp1TE2VTx?= M{LpOIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NFPXcpIzPjB3NUOwNy=>
ROSA KIT WT  M4HHbWFxd3C2b4Ppd{BCe3OjeR?= MXGyNFAuPTByMDDuUS=> NXLIeHpDPDhiaB?= MYfEUXNQ Mof0bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MXmyOlA2PTNyMx?=
ROSA KIT D816V MUXBdI9xfG:|aYOgRZN{[Xl? NU[wUGE1OjByLUWwNFAhdk1? MoTNOFghcA>? M3rjO2ROW09? NIHtcldqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M3rJeFI3ODV3M{Cz
494H NGfaeVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFviXGE4OiCq NXvoVVFOTE2VTx?= Moj3TWM2OD1yLkGyNuKyOC5yMESg{txO MoXiNlU6PDR3Nk[=
493H MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXG3NkBp NEHnOYlFVVOR M3XMOWlEPTB;MD6wOFfDuTBwMEC5JO69VQ>? MkKxNlU6PDR3Nk[=
716H NIDzPXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUe3NkBp MWTEUXNQ NVTHN5JUUUN3ME2wMlIyOsLzMD6wN|Qh|ryP NGjjbnczPTl2NEW2Oi=>
148I NIqyNHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLqSpU4OiCq NGC2SIpFVVOR MlnQTWM2OD1yLkK4OOKyOC5yM{Wg{txO NHfEUJUzPTl2NEW2Oi=>
98Sc M3vnXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\ZO|IhcA>? NULXWoRGTE2VTx?= NYTRToJKUUN3ME2wMlEyPcLzMD6wNFQh|ryP NIO3VogzPTl2NEW2Oi=>
89R M1XGO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TSeVczKGh? NGP0VnZFVVOR MVfJR|UxRTBwMUK2xtExNjByMzFOwG0> M1\GNFI2QTR2NU[2
494L MnLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XZRlczKGh? MUTEUXNQ M3LVRWlEPTB;MD6zNVfDuTBwMEGyJO69VQ>? M3\UblI2QTR2NU[2
493L MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELncYQ4OiCq M3HFTWROW09? NFzlVmtKSzVyPUCuNFUxyrFyLkCxNUDPxE1? NWf5[4VDOjV7NES1OlY>
148L MkXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TW[FczKGh? MkWwSG1UVw>? M2nGV2lEPTB;MD6xOFbDuTBwMEG3JO69VQ>? M3XCNVI2QTR2NU[2
98L M2C4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LjSVczKGh? MorPSG1UVw>? MYnJR|UxRTBwM{C5xtExNjB{OTFOwG0> M1LYclI2QTR2NU[2
OS17 M2HZbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWW3NkBp NH\aUWtFVVOR NULv[XhbUUN3ME2wMlA4QcLzMD6wNFMh|ryP MnTXNlU6PDR3Nk[=
OS9 NV7PNHBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDYeYViPzJiaB?= MX7EUXNQ M3nDRWlEPTB;MD60NFbDuTBwMEK4JO69VQ>? NEC4TVUzPTl2NEW2Oi=>
MG63 MnOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWi3NkBp NX7YOlVWTE2VTx?= NInNeoZKSzVyPUCuNVE1yrFyLkCyOUDPxE1? NXWyV|B3OjV7NES1OlY>
SAOS2 M4G0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU[3NkBp M{O3c2ROW09? Mnj1TWM2OD1yLkKxO:KyOC5yMEOg{txO NYrnZVd[OjV7NES1OlY>
U2OS M{DjOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWG3NkBp MofsSG1UVw>? NWexWGdoUUN3ME2wMlE6QMLzMD6wNFgh|ryP M1PxdlI2QTR2NU[2
SJSA-1 MnXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF:3Rmk4OiCq M3TFbWROW09? MnXLTWM2OD1yLkGwNOKyOC5yMUCg{txO MoXZNlU6PDR3Nk[=
494H Mm\RRZBweHSxc3nzJGF{e2G7 M33JdlAvOjVxMD61M|EvOCEQvF2= Mmr1NlQhcA>? MWjEUXNQ MVrpcoNz\WG|ZYOgcIV3\Wy|IH;mJINt\WG4ZXSgZ4F{eGG|ZT2zxsA> MVeyOVk1PDV4Nh?=
148I NEX4OmFCeG:ydH;zbZMhSXO|YYm= NUnWPWtZOC5{NT:wMlUwOS5yIN88US=> M4T3TFI1KGh? NG\ZZ4JFVVOR MoPsbY5kemWjc3XzJIxmfmWuczDv[kBkdGWjdnXkJINie3Cjc3WtN:Kh MmnmNlU6PDR3Nk[=
OS17 MWPBdI9xfG:|aYOgRZN{[Xl? NXzRfHZiOC5{NT:wMlUwOS5yIN88US=> NH7mVoszPCCq NELvUFZFVVOR MVHpcoNz\WG|ZYOgcIV3\Wy|IH;mJINt\WG4ZXSgZ4F{eGG|ZT2zxsA> MmSwNlU6PDR3Nk[=
494H MVLBdI9xfG:|aYOgRZN{[Xl? MYGx5qCK|ryP NYLJdnZ3PDhiaB?= MmPaSG1UVw>? NEi5OW9qdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPp[45q\mmlYX70cJk> NHzYUXYzPTl2NEW2Oi=>
148I MlX3RZBweHSxc3nzJGF{e2G7 NHH3RpMy6oDLzszN MXq0PEBp MVjEUXNQ MUHpcoR2[2W|IHPlcIwh[XCxcITvd4l{KHOrZ37p[olk[W62bIm= M3jKPVI2QTR2NU[2
OS17 Mmi0RZBweHSxc3nzJGF{e2G7 MmG5NgKBkc7:TR?= NV;WOFRTPDhiaB?= M3zUeGROW09? NInrNGFqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPp[45q\mmlYX70cJk> MmXiNlU6PDR3Nk[=
MOLM13 MmLaRZBweHSxc3nzJGF{e2G7 MX6yOVAhdk1? M4e1b|Q5KGh? NYDMPYVQTE2VTx?= M13HZYlv\HWlZYOgd4lodmmoaXPhcpRtgSCjcH;weI9{cXNiY3;0doVifG2nboSge4l1cCCzdXn6ZZJ1cW6rYh?= MXWyOVA2Ozh{NR?=
MV4-11  Ml\2RZBweHSxc3nzJGF{e2G7 MmTWNlUxKG6P NUW3RWFHPDhiaB?= M{\jbGROW09? MnXibY5lfWOnczDzbYdvcW[rY3HueIx6KGGyb4D0c5NqeyClb4Ty[YF1dWWwdDD3bZRpKHG3aYrhdpRqdmmk M4Xt[lI2ODV|OEK1
MOLM13 NYH1bmhTTnWwY4Tpc44hSXO|YYm= NXvNW2FPOjVyIH7N M3T0TlI1KGh? M4m2cGROW09? Mnz0[Y5p[W6lZYOgdZVqgmG{dHnubYIucW6mdXPl[EBud3KnIICyNUwhSkmPLDDhcoQh[2ynYY\l[EBRSVKS M33FRVI2ODV|OEK1
MV4-11  MUXGeY5kfGmxbjDBd5NigQ>? NGHPbm0zPTBibl2= MXqyOEBp Moj1SG1UVw>? NHzUS3VmdmijbnPld{ByfWm8YYL0bY5q[i2rbnT1Z4VlKG2xcnWgdFIyNCCESV2sJIFv\CClbHXheoVlKFCDUmC= MVyyOVA2Ozh{NR?=
MOLM13 MnW1RZBweHSxc3nzJGF{e2G7 MkD3NlUxKG6P NFvYdms1QCCq MVPEUXNQ MWjpcoR2[2W|IIPp[45q\mmlYX70cJkh[XCxcITvd4l{KGOxdILlZZRu\W62IIfpeIgheG:wYYTpcolj NETMUXYzPTB3M{iyOS=>
MV4-11  NXjlc2NTSXCxcITvd4l{KEG|c3H5 MlrNNlUxKG6P NEPNbW41QCCq MXLEUXNQ NV35XJJ5cW6mdXPld{B{cWewaX\pZ4FvfGy7IHHwc5B1d3OrczDjc5Rz\WG2bXXueEB4cXSqIIDvcoF1cW6rYh?= NH21SGwzPTB3M{iyOS=>
Hela MVPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NHzKeJQxNTVyMDDuUS=> MnnvO|IhcA>? MVLEUXNQ MV;k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NXnMW4ZGOjVyMEmyPVU>
HBL-1 Mmf0R4VtdCCYaXHibYxqfHliQYPzZZk> MmG1NE02ODBibl2= M1myRlczKGh? M1ns[GROW09? Mlny[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NUXaXZN1OjVyMEmyPVU>
HLY-1 NX;iT4Y1S2WubDDWbYFjcWyrdImgRZN{[Xl? M{TVNVAuPTByIH7N MnPWO|IhcA>? NHrWeWRFVVOR MXHk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NWDMcnNkOjVyMEmyPVU>
OCI-Ly3 NHXTc2lE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2XOVFAuPTByIH7N MofHO|IhcA>? MXnEUXNQ NFn3SWFl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MWSyOVAxQTJ7NR?=
OCI-Ly10 NX74TFFXS2WubDDWbYFjcWyrdImgRZN{[Xl? MWSwMVUxOCCwTR?= MkixO|IhcA>? Mmf2SG1UVw>? NUDifXdW\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MWCyOVAxQTJ7NR?=
SU-DHL-4 M4W2TGNmdGxiVnnhZoltcXS7IFHzd4F6 M1rUeVAuPTByIH7N MVi3NkBp NFm2RnJFVVOR NHO4d|Nl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NVXkeGdpOjVyMEmyPVU>
SU-DHL-5 NXr1VGtvS2WubDDWbYFjcWyrdImgRZN{[Xl? NGPSeYwxNTVyMDDuUS=> MYO3NkBp MWLEUXNQ NY\wWYpJ\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M124cFI2ODB7Mkm1
SU-DHL-6 MoHYR4VtdCCYaXHibYxqfHliQYPzZZk> M3Gzd|AuPTByIH7N MonCO|IhcA>? NF\HWFZFVVOR M4HnU4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MoLWNlUxODl{OUW=
SU-DHL-10 NIjtT3BE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NV;JdYJZOC13MECgcm0> NGfRZnc4OiCq MoTySG1UVw>? M{DJWIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MY[yOVAxQTJ7NR?=
RC-K8 Ml\KR4VtdCCYaXHibYxqfHliQYPzZZk> NFGzXIcxNTVyMDDuUS=> NHP6RZk4OiCq NHHzdWlFVVOR M3S2OoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NFjONmozPTByOUK5OS=>
OCI-Ly8 MmHBR4VtdCCYaXHibYxqfHliQYPzZZk> NHLS[W0xNTVyMDDuUS=> NHzQ[|Q4OiCq NILRXpNFVVOR Mk[0[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M{K4PVI2ODB7Mkm1
OCL-Ly18 M1jwOWNmdGxiVnnhZoltcXS7IFHzd4F6 NFW3cnoxNTVyMDDuUS=> Mn\2O|IhcA>? MoT2SG1UVw>? Ml21[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NWLWVpRnOjVyMEmyPVU>
OCI-Ly3 NFjifmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{L2R|E4Oi9{NUCvOVAxKG6P MV[yM|ch\A>? NVvKVW96TE2VTx?= M2HXeolv\HWlZYOgZ4VtdC2leXPs[UBienKnc4SgZZQhe3WkLVexJJdqfGhibXnubY1idCClZXzsJIRm[XSqwrC= NE\Qd|YzPTByOUK5OS=>
OCI-Ly8 M3jidmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXzNVczNzJ3MD:1NFAhdk1? NGXke4QzNzdiZB?= NFPDRWpFVVOR NVniV3lRcW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeEBifCC|dXKtS|Ehf2m2aDDtbY5qdWGuIHPlcIwh\GWjdHlCpC=> NXTpeGIyOjVyMEmyPVU>
SU-DHL-4 NIrvdHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPsSnMyPzJxMkWwM|UxOCCwTR?= MoHlNk84KGR? NH\kcWNFVVOR NXXob5JMcW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeEBifCC|dXKtS|Ehf2m2aDDtbY5qdWGuIHPlcIwh\GWjdHlCpC=> NE\sVoUzPTByOUK5OS=>
SU-DHL-10 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzONVczNzJ3MD:1NFAhdk1? MkP6Nk84KGR? NH2wcWZFVVOR NFPrbYRqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0JIF1KHO3Yj3HNUB4cXSqIH3pcolu[WxiY3XscEBl\WG2aNMg MlTGNlUxODl{OUW=
OCI-Ly3 M1HiVGFxd3C2b4Ppd{BCe3OjeR?= M{LpUlE4Oi9{NUCgcm0> MnnMO4Q> MofFSG1UVw>? MlPjbY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC|aXfubYZq[2GwdHz5 MWeyOVAxQTJ7NR?=
OCI-Ly8 MknaRZBweHSxc3nzJGF{e2G7 M1HRdVE4Oi9{NUCgcm0> NEixXoE4\A>? NFXIPJNFVVOR M13iOIlv[3KnYYPld{Bk[XOyYYPlMVMwPyCjY4Tpeol1gcLic3nncolncWOjboTsfS=> M2DBRVI2ODB7Mkm1
SU-DHL-4 NXTmNYFjSXCxcITvd4l{KEG|c3H5 M4G3VFE4Oi9{NUCgcm0> MmLEO4Q> NUHRTXkzTE2VTx?= NUK2eZNbcW6lcnXhd4V{KGOjc4Dhd4UuOy95IHHjeIl3cXS7wrDzbYdvcW[rY3HueIx6 NYL2XG8yOjVyMEmyPVU>
SU-DHL-10 Mn7DRZBweHSxc3nzJGF{e2G7 NG[5PFkyPzJxMkWwJI5O M3[wbldl MVzEUXNQ NFvJXllqdmO{ZXHz[ZMh[2G|cHHz[U0{NzdiYXP0bZZqfHoEoIPp[45q\mmlYX70cJk> MYWyOVAxQTJ7NR?=

... Click to View More Cell Line Experimental Data

In vivo (+)-JQ1 (50 mg/kg) inhibits tumors growth in mice with NMC 797 xenografts. (+)-JQ1 (50 mg/kg) results in effacement of NUT nuclear speckles in mice with NMC 797 xenografts, consistent with competitive binding to nuclear chromatin. (+)-JQ1 (50 mg/kg) induces strong (grade 31) keratin expression in NMC 797 xenografts. (+)-JQ1 (50 mg/kg) promotes differentiation, tumor regression and prolonged survival in mice models of NMC xenografts. [1] (+)-JQ1 (50 mg/kg) results in a significant prolongation in overall survival of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells compared to vehicle-treated animals. [2] (+)-JQ1 (50 mg/kg i.p.) leads to a highly significant increase in survival of mice bearing Raji xenografts. [3]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: MC 11060 cells
  • Concentrations: ~500 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism).


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Mice bearing NMC 797 xenografts
  • Formulation: 5% DMSO in 5% dextrose
  • Dosages: 50 mg/kg
  • Administration: intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 91 mg/mL warmed (199.12 mM)
Ethanol 91 mg/mL (199.12 mM)
Water Insoluble
In vivo Add solvents individually and in order:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 456.99
Formula

C23H25ClN4O2S

CAS No. 1268524-70-4
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can I reconstitute the compound for in vivo injection?

  • Answer:

    JQ1 does not dissolve in water/PBS. The vehicle we recommend is 2% DMSO+30% PEG 300+5% Tween 80+ddH2O. The compound can be dissolved in the vehicle at 5mg/ml and you can use it for IV injection.

Related Antibodies

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy (+)-JQ1 | (+)-JQ1 supplier | purchase (+)-JQ1 | (+)-JQ1 cost | (+)-JQ1 manufacturer | order (+)-JQ1 | (+)-JQ1 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID